Merck Tagged Articles
British Columbia refuses to cover some type 2 diabetes drugs
The British Columbia Medical Beneficiary and Pharmaceutical Services Division has delisted all sitagliptin drugs, including Januvia and Janumet, from its Pharmacare Benefits Program and will adjust its coverage of all other diabetes drugs in the class by February 2015. The
Merck reaches $100 million settlement in NuvaRing side effects lawsuits
A $100 million settlement involving life threatening side effects from Merck’s NuvaRing birth control device will stand now that a vast majority of claimants have agreed to the terms of the settlement.
FDA panel votes against approval of Singulair Allergy for OTC use
A Food and Drug Administration (FDA) advisory panel is recommending that the agency not approve Merck’s Singulair Allergy drug for over-the-counter treatment for allergic rhinitis because of safety concerns.
FDA panel recommends approval of new blood thinner despite serious side effects
A Food and Drug Administration (FDA) advisory panel stunned analysts last week by voting to recommend the approval of an experimental new blood thinner from Merck despite concerns about serious side effects such as internal bleeding.
Pharmaceutical investors should look for alternatives to statin medications
Investors wanting to win big in the pharmaceutical market should look to new kinds of LDL, or “bad” cholesterol, treatments instead of putting money toward new or existing cholesterol-lowering statin drugs, Motley Fool advises.
Januvia sales may be threatened by pancreatitis, pancreatic cancer risk
Drug maker Merck is putting most of its earnings “eggs” in one basket – Januvia, a type 2 diabetes drug – after its top-selling Singular went off patent protection and generic competition moved in. However analysts are unsure Januvia can
Generic Fosamax failed to warn that use could result in rare femur fracture
Federal law does not stand in the way of a product liability lawsuit alleging the makers of a generic version of the osteoporosis drug Fosamax failed to update its warning label to conform with a revised label on the brand-name
FDA to review new type 2 diabetes treatment
The Food and Drug Administration (FDA) has started a review of Sanofi’s new once-daily type 2 diabetes drug lixisenatide. The drug was approved last month by European Union regulators, and will be marketed as Lyxumia. Sanofi has not yet selected
Fosamax maker ordered to pay $285,000 to woman who developed severe jawbone disease
Merck, makers of the osteoporosis drug Fosamax, was ordered to pay $285,000 to a woman who claimed the drug caused her to develop osteonecrosis of the jaw (ONJ) after dental surgery and that the company did not adequately warn about
Merck seeks approval for previously rejected combination cholesterol drug
Merck & Co. is resubmitting the drug application for its combination cholesterol-lower drug MK-0653C, which was rejected by the Food and Drug Administration (FDA) last March due to insufficient data.